Paralel Advisors LLC Takes $3.17 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Paralel Advisors LLC purchased a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 9,937 shares of the biotechnology company’s stock, valued at approximately $3,165,000. United Therapeutics accounts for about 0.2% of Paralel Advisors LLC’s holdings, making the stock its 24th largest position.

Other institutional investors also recently made changes to their positions in the company. V Square Quantitative Management LLC bought a new position in shares of United Therapeutics in the 2nd quarter worth about $30,000. Rise Advisors LLC bought a new stake in United Therapeutics in the first quarter valued at $32,000. Innealta Capital LLC acquired a new position in shares of United Therapeutics during the second quarter valued at $33,000. Benjamin F. Edwards & Company Inc. grew its position in shares of United Therapeutics by 63.6% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 117 shares during the last quarter. Finally, Janiczek Wealth Management LLC increased its holdings in shares of United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 84 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have commented on UTHR. LADENBURG THALM/SH SH lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $310.00 to $321.00 in a research report on Thursday, July 11th. UBS Group increased their price target on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. Wells Fargo & Company increased their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. Finally, JPMorgan Chase & Co. upped their price target on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 21st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $350.36.

United Therapeutics Trading Down 1.3 %

Shares of UTHR stock traded down $4.38 during trading hours on Friday, reaching $345.63. 275,774 shares of the stock traded hands, compared to its average volume of 492,118. The business has a fifty day moving average price of $333.83 and a 200 day moving average price of $283.31. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $366.08. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $15.33 billion, a PE ratio of 16.34, a PEG ratio of 1.28 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). The business had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period last year, the business earned $5.24 EPS. On average, equities research analysts forecast that United Therapeutics Co. will post 24.86 EPS for the current year.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $273.95, for a total transaction of $986,220.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $35,613.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, COO Michael Benkowitz sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total value of $8,084,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $833,350.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $273.95, for a total transaction of $986,220.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $35,613.50. The disclosure for this sale can be found here. Insiders have sold 119,520 shares of company stock worth $38,572,141 in the last 90 days. Company insiders own 12.50% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.